Concurrent radiotherapy and tumor targeting with 111In-HMFG1- F(ab')2 in patients with MUC1-positive non-small cell lung cancer

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4663-4671

  Garkavij, Michael ^a   Samarzija, Miroslav ^b   Ewers, Sven B ^a   Jakopovic, Marko ^b   Tezak, Stanko ^b   Tennvall, Jan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KBC Zagreb   (Croatia)

Author keywords

111InHMFG1 F(ab')2; Biodistribution; Lung cancer; Lysine; Radiotherapy

Indexed keywords

HMFG1 F(AB')2 CITC DTPA; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; INDIUM 111; LYSINE; MUCIN 1; PENTETIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BLOOD ANALYSIS; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HUMAN; IMAGE ANALYSIS; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MORBIDITY; NEPHROTOXICITY; OPEN STUDY; PRIORITY JOURNAL; PUBLICATION; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; TARGET CELL; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; AMINO ACIDS; ANTIBODIES, MONOCLONAL; CA-15-3 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INDIUM RADIOISOTOPES; ISOTHIOCYANATES; KIDNEY; LIVER; LUNG NEOPLASMS; LYSINE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 28444431500     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. American Cancer Society: Cancer Facts & Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf.
2. Ferlay J, Parkin DM, Pisani P and Globocan L: Cancer Incidence and Mortality World-wide, IARC Press: Lyon 1998 and Landis SH et al: CA Cancer J Clin 49: 8-31, 1999.
3. Greenlee RT, Murray T, Bolden S and Wingo PA: The Surveillance Research Program of the American Cancer Society's Department of Epidemiology and Surveillance Research reports its annual compilation of estimated cancer incidence, mortality, and survival data for the United States in the year 2000. CA Cancer J Clin 50: 7-33, 2000.
4. Stevens CW, Lee JS, Cox J and Komaki R: Novel approaches to locally advanced unresectable non-small cell lung cancer. Radiother Oncol 55: 11-18, 2000.
5. Buchegger F, Roth A, Allal A et al: Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy. Ann NY Acad Sci 910: 263-270, 2000.
6. Kalofonos H, Rowlinson G and Epenetos AA: Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation. Cancer Res 50: 159-163, 1990.
7. Behr TM, Goldenberg DM and Becker W: Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 25: 201-212, 1998.
8. DeNardo SJ, O'Donnell RT and DeNardo GL: Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates. J Nucl Med 37: 829-833, 1996.
9. Behr Th, Becker W, Sharkley R et al: Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 37: 829-833, 1996.
10. Behr Th, Sharkey RM, Sgouros G et al: Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 80: 2591-2610, 1997.
11. 18F-labelled anti-tac disulfide- stabilised Fv. Cancer Res 58: 2612-2617, 1998.
12. Kabayashi H, You TM, Kim IS et al: Favorable effect of lysine on biodistribution and metabolism of Tc-99m dsFv. J Nucl Med 37: 129s, 1996.
13. 86Y-DOTAO)-D-Phel-Tyr3- octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med 30: 510-518, 2003.
14. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ and Hilgers J: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Res 11: 55-101, 1988.
15. Siegel JA, Thomas SR, Stubbs JB et al: MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40: 37-61S, 1999.
16. Cloutier RJ, Smith SA, Watson EE, Snyder WS and Warner GG: Dose to the fetus from radionuclides in the bladder. Health Phys 25: 147-161, 1973.
17. 111In-labeled HMFG1 F(ab')2 fragments. Cancer Res 48: 1977-1984, 1988.
18. Buchegger F, Rojas A, Delaloye AB, Vogel CA et al: Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res 55: 83-89, 2000.
19. Znati CA, Rosenstein M, McKee TD et al: Irradiation reduces interstitial fluid transport and increases the collagen content in tumors. Clin Cancer Res 9: 5508-5513, 2003.
20. Ruan S, O'Donoghue J, Larson SM et al: Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. JNM 41: 1905-1912, 2000.
21. Sun LQ, Vogel CA, Mirimanoff RO, Coucke P, Mach JP and Buchegger F: Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice. Cancer Res 57: 1312-1319, 1997.
22. Mojiminiyi SA, Shepstone BJ and Soper ND: Human antimurine antibodies (HAMA) in vivo complex formation and the outcome of immunoscintigraphy. J Nucl Med 31: 381-382, 1990.
23. Rettenbacher L and Galvan G: Anaphylactic shock after repeated injection of 99mTc-labeled CEA antibody (in German). Nuklearmedizin 33: 127-128, 1994.
24. Sakahara H, Reynolds JC, Carrasquillo JA et al: In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med 30: 1311-1317, 1989.
25. Frodin J-E, Faxas M-E, Hagström B et al: Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome - an important antitumoral effector function? Hybridoma 10: 421-431, 1991.
26. Gruber R, van Haarlem LJ, Warnaar SO, Holz E and Riethmuller G: The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res 60: 1921-1926, 2000.